Clinical Utility Study for Exo-PDAC

Pancreas Cancer Clinical Trial

Official title:

Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Biological Dynamic's Exo-PDAC Test: A CPV® Randomized Controlled Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05702385
• Other study ID #: Pro00068105
• Status: Withdrawn
• Phase: N/A
• Start date: September 1, 2023
• Est. completion date: October 31, 2023

Study information

• Verified date: November 2023
• Source: Qure Healthcare, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a national-level research study of oncologists, interventional gastroenterologists, and primary care providers. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

Description:

The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidance. The data from this study will be submitted to a national journal for publication. The study plans to enroll up to 250 physicians.

Upon consenting and agreeing to participate in this study, participants will be asked to care for 3 simulated patient cases, known as Clinical Performance and Value Vignettes (CPV®). CPV®s describe patients physicians typically encounter in their daily practice and are not meant to be difficult. In each vignette, physicians are asked to share their expected care through 5 domains: 1) history, 2) physical exam, 3) diagnostic workup, 4) diagnosis and 5) treatment and follow-up. Each case takes approximately 15-20 minutes to complete and we estimate the time commitment for each round of CPV® administration to be approximately 45 - 60 minutes. All responses to the cases will be completed online and will be kept confidential. Over 2 CPV® administration rounds, the total time to care for the simulated patients is estimated at 1.5-2 hours.

If physicians are randomized to an intervention group in this study, they will receive educational materials on a novel diagnostic test after the first round of CPV® administration. They are asked to review these materials before moving to the next CPV® administration round. The time to review educational materials is estimated to be approximately 15 minutes.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 31, 2023
• Est. primary completion date: October 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Board-certified for at least two years

• Averaging at least 20 hours per week of clinical and patient care duties over the last six months

• Routinely evaluate patients at risk for pancreatic cancer in their practice

• Practicing in the U.S.

• English speaking

• Access to the internet

• Informed, signed, and voluntarily consented to be in the study

Exclusion Criteria:

• Non-English speaking

• Unable to access the internet

• Not practicing in the U.S.

• Not averaging at least 20 hours per week of clinical or patient care duties over the last six months

• Previous exposure to the test

• Do not voluntarily consent to be in the study

Related Conditions & MeSH terms

• Pancreas Cancer
• Pancreatic Neoplasms

Intervention

Other:
• Educational Materials for a new diagnostic test
These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.

Locations

Country	Name	City	State
United States	QURE Healthcare	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Qure Healthcare, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Performance and Value (CPV)-measured variation in Assessment	Measure variation in the number and quality of clinical decisions among practicing oncologists, primary care physicians, and interventional gastroenterologists in the assessment, surveillance, and management of patients at high risk of developing PDAC. The number and quality of clinical decisions will be measured on a scale of 0-100 where higher numbers represent closer adherence to evidence base national guidelines.	[4 months]
Primary	CPV-measured change in treatment Quality	Measure of the difference in quality of overall diagnostic scores between control physicians using standard of care diagnostic tools and intervention physicians using the diagnostic test.	[4 months]
Primary	CPV-measured variation in evidence based decisions between control and intervention arms	Measure of the difference in number of evidence-based decisions made by intervention physicians versus control physicians, while controlling for physician and practice characteristics, between rounds 1 and 2.	[4 months]
Primary	CPV-measured variation in evidence based decisions between intervention arms	Measure the differences in amount of evidence-based decisions made by intervention group one physicians versus intervention group two physicians to assess whether the choice to order the test impacts the overall patient care and outcomes.	[4 months]
Primary	CPV-measured rate of adoption for the diagnostic test	Rate of adoption of the test after receiving educational materials on the benefits of testing in patients who are at risk.	[4 months]
Primary	CPV-measured differences in cost of care between control and intervention arms	Difference in the cost of care between control and intervention physicians (Cost will be calculated by measuring differential rates of medical interventions/levels of care selected by each arm, and multiplying by Medicare reimbursement rates for these interventions, and/or by modeling the incidence of expected complications and calculating associated costs per above).	[4 months]